Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solifenacin in overactive bladder syndrome.

Christopher K Payne1

  • 1Section of Female Urology and NeuroUrology, Stanford University School of Medicine, Stanford, California 94305-5118, USA.

Drugs
|February 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of persistent urinary incontinence after successful fistula closure in Ethiopian women.

International urogynecology journal·2020
Same author

Capacity building in female pelvic medicine and reconstructive surgery: Global Health Partnership beyond fistula care in Ethiopia.

International urogynecology journal·2020
Same author

International continence society white paper regarding female genital mutilation/cutting.

Neurourology and urodynamics·2019
Same author

Urinary Urgency in the Elderly.

Gerontology·2018
Same author

An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD).

Neurourology and urodynamics·2017
Same author

A review of the current status of laparoscopic and robot-assisted sacrocolpopexy for pelvic organ prolapse.

European urology·2014

Solifenacin succinate effectively treats overactive bladder (OAB) symptoms like frequency and incontinence. This well-tolerated medication improves quality of life and patient adherence to treatment.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Overactive bladder (OAB) syndrome significantly impacts quality of life and incurs substantial healthcare costs.
  • Antimuscarinic agents are standard OAB treatment but often have poor patient compliance due to adverse events.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of solifenacin succinate, a novel antimuscarinic agent, for OAB treatment.

Main Methods:

  • Multiple clinical trials were conducted to assess solifenacin's effects on OAB symptoms.
  • Patient persistence with therapy was evaluated through open-label extension studies.

Main Results:

  • Solifenacin treatment led to statistically significant reductions in OAB symptoms (frequency, urgency, incontinence) and increased voided volume.

Related Experiment Videos

  • The drug was well-tolerated, with mild and infrequent adverse effects, leading to high patient persistence (81% in extension study).
  • In vitro studies showed bladder selectivity, and pharmacokinetic studies in healthy men indicated extensive absorption.

    • Conclusions:

    • Solifenacin succinate is a well-tolerated and efficacious treatment for OAB.
    • It significantly reduces OAB symptoms, improves patient quality of life, and promotes treatment adherence.